Drug Development and Transactional Deal Landscape for Neurodegenerative Disorders
Neurodegenerative disorders (NDDs) impact a significant number of the US and the global population and are the leading cause of disability and morbidity in the US. There is a long history of failed attempts to develop effective therapies, and currently, there are no treatments that can prevent, slow down or cure NDD.
Here we present an in-depth analyses of the current development pipeline for AD, PD, HD, and ALS by phase and mechanism of action with the focus on symptomatic versus disease modifying approaches. Furthermore, we provide insights on the challenges in the drug development for NDD and how they can be addressed.